Introduction
Normal and aberrant growth of breast epithelial cells is controlled by receptors of both steroid hormones and peptide growth factors. The ErbB family of receptor tyrosine kinases (RTKs), including the epidermal growth factor (EGF) receptor (EGFR; HER-1/erbB-1), human EGF receptor HER-2 (erbB-2), HER-3 (erbB-3), and HER-4 (erbB-4) are frequently implicated in human cancers (Hynes and Stern, 1994; Gilbertson et al., 1998) . These receptors are activated by growth factor binding, dimerization, and tyrosine autophosphorylation of the cytoplasmic C-terminal domain (Heldin and Ostman, 1996; Schlessinger et al., 1988) providing docking sites for cytoplasmic effectors of intracellular signaling (van der Geer et al., 1994; Riese and Stern, 1998; Klapper et al., 2000; Sweeney et al., 2001) . Over a dozen growth factors activate the erbB receptors, typified by EGF that directly binds to the EGF receptor, and heregulins (HRGs) also called neu differentiation factors that directly bind to HER-3 and HER-4 receptors (Tzahar et al., 1994; Riese and Stern, 1998) . The ErbB family also forms heterodimeric receptors with HER-2, an orphan coreceptor, as the preferred partner (Plowman et al., 1993; Sliwkowski et al., 1994; Karunagaran et al., 1996; Graus-Porta et al., 1997) .
Abnormalities in the expression levels of ErbB receptors, particularly HER-2, are frequently encountered in a number of human cancers. The HER-2 gene is amplified in 20-30% of breast carcinomas, where it contributes to more aggressive disease (Slamon et al., 1989) . Elevated HER-2 promotes the formation of HER-2 containing heterodimers that display amplified signaling Karunagaran et al., 1996; Pinkas-Kramarski et al., 1998) . HER-2 heterodimerizes with the HRG receptor HER-3 to initiate the most potent oncogenic signaling cascades (Alimandi et al., 1995; Wallasch et al., 1995; Pinkas-Kramarski et al., 1996; Tzahar et al., 1996) and this receptor combination may be particularly important in driving the malignant progression of mammary tumors (Alimandi et al., 1995; Siegel et al., 1999; Hijazi et al., 2000; Ram et al., 2000; Xiong et al., 2001 ).
About 75% of breast carcinomas are estrogen receptor (ER) positive and initially respond to therapy with the antiestrogenic drug tamoxifen (Dowsett, 2001 ). However, hormonal resistance often develops and is a serious clinical problem. Crosstalk between steroid hormone and erbB receptor pathways contributes to the development of hormone independence (Dowsett, 2001; Dowsett et al., 2001) . The ectopic expression of HER-2 (Pietras et al., 1995; Kurokawa et al., 2000) or HRG (Tang et al., 1996; Mazumdar et al., 2001) in estrogen-responsive breast carcinoma cells induces estrogen independence and resistance to tamoxifen.
The HER-2 gene, in addition to encoding the fulllength receptor, also encodes an alternate product, herstatin (Hst), created by intron retention (Doherty et al., 1999) . Hst consists of the first two subdomains of the HER-2 ectodomain and an intron-encoded C-terminus that confers binding to HER-2 itself as well as to HER-1 (Doherty et al., 1999; Azios et al., 2001) . The expression of Hst appears to be regulated, since it is relatively low in breast carcinoma cells with HER-2 gene amplification and is expressed at high levels in a tissuespecific manner in fetal kidney and liver (Doherty et al., 1999) . Hst has been found to block HRG-mediated HER-2/HER-3 heterodimer formation in a dominantnegative manner in transiently transfected nontumorigenic cells (Azios et al., 2001) . However, the impact of this alternative HER-2 product on signaling and proliferation of breast carcinoma cells has not yet been investigated. The present study demonstrates that Hst expression or treatment with purified Hst signaled loss of HRG receptors and inhibition of HRG-mediated growth of breast cancer cells with and without HER-2 overexpression. Moreover, Hst restored the growth inhibitory effects of the antiestrogenic drug tamoxifen to HER-2 overexpressing breast cancer cells.
Results

Expression of Hst in MCF7 clonal cell lines
The effects of Hst on erbB receptor-mediated signaling and cell growth have previously been investigated in nontumorigenic cells transfected with erbB receptors, in combination with Hst (Azios et al., 2001; Justman and Clinton, 2002) . Efforts to examine the effects of Hst expression in a variety of carcinoma cells that depend on erbB receptors for proliferation have been hindered, since even very low levels of Hst prevent their survival. We therefore chose the MCF7 cells to investigate the impact of Hst activity on breast cancer cells, since these cells depend on estrogens for proliferation (Read et al., 1990) , and express low levels of all four erbB receptors Jeschke et al., 1995) . Figure 1a illustrates the intracellular expression of B60 kDa Hst in two stably transfected MCF7 clonal cell lines, MCF7/ Hst(1) and MCF7/Hst(2). The parental MCF7 cells expressed no detectable Hst, while the Hst(1) clone expressed about 10-fold more than Hst(2) (Figure 1a) . Moreover, Hst was secreted in proportion to the cellassociated levels ( Figure 1a ) and reached a concentration of about 2 nm in media exposed to MCF7/Hst(1) cells for 3 days. , and extracted at the indicated times for Western blot analysis using antibodies specific for phospho-MAPK and total MAPK. (d) MCF7 cell lines were serum starved for 24 h, incubated in the absence or presence of FGF-2 (50 ng/ml) at 371C for the indicated times, and then analysed as a Western blot using antibodies specific for phospho-MAPK and total MAPK Herstatin blocks heregulin growth and enhances tamoxifen sensitivity Hst has been shown to block HRG and EGF activation of ErbB receptors in nontransformed cells (Azios et al., 2001; Justman and Clinton, 2002) . To determine whether Hst inhibited HRG signaling in MCF7 breast carcinoma cells, we examined the activation of two major proliferative and survival pathways, as indicated by levels of phosphorylated MAPK and Akt. We focused on HRG signaling since HER-3 and HER-2 are the main ErbB receptors in MCF7 cells (Plowman et al., 1993; Sliwkowski et al., 1994; Karunagaran et al., 1996) . HRG strongly activated the Akt survival pathway in the parental MCF7 cells, whereas no phosphorylated Akt was detected in the cell line that produced either high or nearly 10-fold lower levels (MCF7/Hst(1) and MCF7/Hst(2), respectively) of Hst (Figure 1b) . While HRG activated MAPK in MCF7 parental cells, it did not stimulate MAPK beyond basal levels in the two cell lines that expressed Hst (Figure 1c ). Since HRG signaling through both the MAPK and Akt pathways was blocked, it was important to examine whether Hstexpressing cells supported signaling through other growth factor receptor families. Both fibroblast growth factor-2 (FGF-2) ( Figure 1d ) and insulin-like growth factor-1 (IGF-1) (data not shown) induced MAPK to comparable levels in the Hst-expressing and parental cells, establishing the integrity of the MAPK pathway and indicating specificity of Hst for erbB receptor intracellular signaling.
Hst inhibited HRG-induced growth
Blockage of two major signaling pathways, MAPK and Akt, suggested possible interference with mitogenic stimulation by HRG. Therefore, the growth response of MCF7 parental and Hst-expressing cells to different concentrations of HRG was examined. HRG induced a dose-dependent increase in the proliferation of parental MCF7 cells (Figure 2a ). In contrast, proliferation was blocked at both low (1 nm) as well as 10-fold higher HRG concentrations (Figure 2a ). These results show for the first time that Hst prevented HRG-mediated proliferation in MCF7 breast carcinoma cells.
To examine the mechanism underlying obstructed HRG signaling and proliferation by Hst, we investigated the level of tyrosine phosphorylation of HER-3, the major HRG receptor in MCF7 cells (Aguilar et al., 1999) . HRG induced receptor tyrosine phosphorylation in parental MCF7 cells (Figure 2b ) as observed in numerous other studies (Sliwkowski et al., 1994; Wallasch et al., 1995; Lewis et al., 1996; Aguilar et al., 1999; Tan et al., 1999) . However, no tyrosine-phosphorylated HER-3 was observed in either MCF7/Hst(1) or MCF7/Hst(2) cell lines ( Figure 2b ). Moreover, tyrosine-phosphorylated HER-2 could not be detected in the Hst-expressing cells (data not shown). Unexpectedly, levels of the HER-3 receptor itself were greatly reduced in Hst-expressing cells as indicated by Western blot analysis (Figure 2b ). In contrast, endogenous HER-2 levels were unabated as a result of Hst expression ( Figure 2b ).
Hst prevented HER-2 mediated enhancement of HER-3 and HER-4
Overexpression of HER-2 in MCF7 cells has been reported to enhance HRG receptors and potentiate growth factor signaling (Lewis et al., 1996; Aguilar et al., 1999) . In agreement, receptor activation, indicated by tyrosine phosphorylated HER-2 and HER-3, was strongly stimulated by HRG treatment of the MCF7/ HER-2 cells, whereas Hst expression eliminated tyrosine-phosphorylated HER-2 and HER-3 ( Figure 3a ). Further, there was an 8-9-fold increase in HER-3 levels (1) Hst (2) MCF7/Hst(1)
MCF7
Hst (1) Hst ( Herstatin blocks heregulin growth and enhances tamoxifen sensitivity F Jhabvala-Romero et al in two different MCF7 cell lines stably transfected with HER-2, even though HER-2 levels were enhanced only about threefold over that in parental cells (Figure 3b ). Introduction of Hst into the two different MCF7/HER-2 cell lines eliminated HER-3, while HER-2 levels were maintained or slightly enhanced (Figure 3b ). The effects of HER-2 and Hst expression on the fate of the other HRG receptor, HER-4, were also investigated by immunoprecipitation followed by immunoblotting transfected and parental MCF7 cells with an antibody specific for HER-4. HER-4 levels, although low in MCF7 cells, appeared to be inhibited by Hst expression (Figure 3c ). In MCF7/HER-2 cells, HER-4 levels were strongly enhanced, as observed for the other HRG receptor HER-3, whereas the introduction of Hst downregulated HER-4 (Figure 3c ). These findings demonstrated that while overexpression of HER-2 stimulated the levels of both HRG receptors, HER-3 and HER-4, the alternative product of HER-2, Hst, reduced the expression of the HRG receptors.
Hst expression restored tamoxifen sensitivity to HER-2 overexpressing MCF7 cells
Numerous studies have found that overexpression of HER-2 leads to hormone nonresponsiveness and insensitivity to the antiestrogen tamoxifen (Benz et al., 1993; Pietras et al., 1995; Dowsett, 2001 ). In accordance with these studies, responsiveness of MCF7/HER-2 cells to tamoxifen treatment was reduced compared to parental MCF7 cells as indicated by quantitation of live cells in triplicate wells by the MTS assay (Figure 4 ). To investigate whether Hst could restore sensitivity, we examined the growth response of Hst-transfected MCF7/HER-2 cells to different concentrations of tamoxifen and observed significantly enhanced sensitivity (Figure 4 ). Since Hst expression in MCF7 as well as MCF7/HER-2 cell lines abolished HRG signaling, the sensitivity of MCF7/Hst cells to tamoxifen was also examined. In this cell line, tamoxifen sensitivity was not enhanced over that displayed by the parental MCF7 cells (Figure 4) .
Exposure of MCF7 cells to extracellular Hst inhibited HER-3 levels
Intracellular or secreted Hst may have inhibited HRG receptor levels, or receptor loss could have occurred during the selection of stably transfected clonal cell lines. To explore the mechanism of HER-3 down- Herstatin blocks heregulin growth and enhances tamoxifen sensitivity F Jhabvala-Romero et al regulation further, MCF7 cells were cocultured with Hst-expressing or parental cells, separated by membrane inserts that allowed exchange of molecules, but prevented direct cell contact. The cells exposed to cocultures for 3 days were then analysed for levels of HER-3. In duplicate samples, secreted material from the Hst transfected, but not the parental MCF7 cells, reduced the HER-3 levels by about 10-fold (Figure 5a) . Reduction of HER-3, but not HER-2, in a second breast carcinoma cell line, BT474, was also caused by cocultivation with MCF7/Hst, but not parental MCF7 cells (Figure 5b ).
Recombinant Hst purified from insect cells inhibited HER-3 levels and blocked HRG-mediated proliferation
To determine whether the purified protein functioned similar to Hst expressed in transfected cells, His-tagged Hst was purified from stably transfected S2 insect cells and added to MCF7 cells. Hst, but not the control vehicle, reduced HER-3 expression within 24 h following treatment of MCF7 (Figure 5c ). We next investigated whether the monoclonal antibody, herceptin, which also blocks HRG signaling in MCF7 cells (Pegram and Slamon, 2000) , may have a similar effect on HER-3 levels. While herceptin downregulated HER-2 itself as previously reported (Arteaga et al., 2001 ), HER-3 was not significantly reduced (Figure 5d ). Therefore, Hst appeared to have the unique action of diminishing levels of HER-3.
Hst treatment obstructed HRG-induced growth of MCF7 and BT474 cells
Purified Hst from insect cells was also examined for effects on HRG-stimulated proliferation. MCF7 and BT474 cells were treated with HRG alone or with different concentrations of Hst. HRG induced a growth response in MCF7 cells with relatively low levels of HER-2 and in BT474 cells that overexpress HER-2. Moreover, Hst treatment inhibited HRG-mediated proliferation in both these cells lines in a doseresponsive manner (Figure 6a, b) .
Discussion
Investigating the impact of ErbB inhibitors on growth factor-mediated receptor activation, intracellular signaling and proliferation are critical for understanding the function of these receptors in human cancers. Studies presented here describe the impact of Hst on major proliferative pathways in breast carcinoma cells with and without HER-2 overexpression and demonstrate unique functions for this inhibitor in the regulation of ErbB receptors.
HRG signaling was blocked by the expression of Hst in both parental and HER-2 overexpressing MCF7 cells, indicated by elimination of tyrosine phosphorylated HER-2 and HER-3. Consistent with lack of receptor activation, intracellular signaling through MAPK and Akt by HRG was also prevented, whereas FGF-2 MAPK activation was unaffected (Figure 1d ), suggesting that the inhibitory effects were through ErbB receptors rather than crosstalk with nonhomologous RTK pathways. Treatment of MCF7 and BT474 cells with Hst purified from S2 insect cells demonstrated that the HRG-induced growth of two different breast cancer cell lines could be blocked from outside the cells, further suggesting the feasibility of developing Hst into an anticancer therapeutic.
Hst-mediated suppression of the HRG receptors in both parental and MCF7/HER-2 cells may entirely explain the loss of HRG-induced signaling and proliferation. HER-3, the predominant HRG receptor in MCF7 cells, initiates a proliferative response, whereas HER-4 has been reported to trigger an antiproliferative response in human breast cancer cells (Sartor et al., 2001) . Hst-mediated loss of proliferation did not appear to be caused by HER-4 antiproliferative signaling, however, since both HER-3 and HER-4 were downregulated by Hst.
Most of the evidence presented in this study suggests that loss of the HRG receptors is caused by interaction of secreted Hst with receptors on the cells' surface. HER-3 was reduced in MCF7 and BT474 cells exposed to media containing secreted Hst or by treatment with levels depend on receptor/receptor interactions. While Hst binds to the ectodomain of HER-2 and HER-1, blocking homodimer and heterodimer formation, preliminary studies suggest that it may not directly bind to HER-3 (Doherty et al., 1999; Azios et al., 2001) . Loss of HER-3 may be caused by disruption of HER-3 heteromeric interactions with HER-2, the major signaling partner in MCF7 cells (Aguilar et al., 1999) . The inability of the HER-2 inhibitor, herceptin, to prevent receptor dimerization may explain its failure to suppress HER-3. It is currently unknown whether purified exogenous Hst binds directly to HER-4, or rather downregulates HER-4 by preventing heteromeric interactions with HER-2. Alternatively, Hst interactions with receptors at the cell surface may initiate novel signals that lead to loss of HRG receptors.
The importance of heteromeric interactions with HER-2 in the regulation of HRG receptors is further suggested by a striking enhancement of HER-3 and HER-4 as a result of a small increase (about threefold) in HER-2 expression in MCF7/HER-2 cells (Figure 3 ). While previous observations support a dominant role for HER-2 in controlling HRG-binding sites and HER-3 levels in MCF7 cells (Lewis et al., 1996; Aguilar et al., 1999) , HER-4 was not found to be increased in response to HER-2 overexpression (Aguilar et al., 1999) . The discrepant effects of HER-2 on HER-4 levels in the two studies may be explained by differences in the MCF7/ HER-2 cell lines. In particular, the extent of HER-2 overexpression was much lower in the MCF7/HER-2 cells used in the current study (about threefold compared to nearly 100-fold over parental). HER-2-mediated HER-3 upregulation in mammary tumorigenesis is further supported by enhanced levels of erbB3 in mammary tumors of neutransgenic mice (Siegel et al., 1999) . Since HER-3 is kinase inactive and incapable of signaling in the absence of other erbB receptors, heteromeric interactions particularly with HER-2 may tightly regulate HER-3 (Guy et al., 1994; PinkasKramarski et al., 1996) .
Hst expression, in addition to blocking HRG signaling, also restored sensitivity to the antiestrogen tamoxifen in HER-2 transfected MCF7 cells. The HER-2 monoclonal antibody herceptin (Nicholson, 2000) , the kinase inhibitor AG1478 (Kurokawa et al., 2000) , and Hst, despite their entirely different mechanisms of action, all confer tamoxifen sensitivity to HER-2 overexpressing MCF7 breast cancer cells. Since growth factor stimulation of MAPK has been shown to contribute to tamoxifen resistance (Bunone et al., 1996; Kurokawa et al., 2000; Lopez et al., 2001) , blockage of erbB receptor stimulation of MAPK signaling cascades by each of these different inhibitors may explain why they all promote tamoxifen sensitivity. Findings presented here, however, show that blocking HRG stimulation of the MAPK pathway by Hst was not sufficient to enhance responsiveness to tamoxifen. MCF7 cells with and without Hst were not significantly different in their response to tamoxifen (see Figure 4) . Therefore, erbB inhibitors may be clinically effective ) were plated into 24-well plates, incubated overnight in 0.5% FBS media, and treated with Hst or vehicle for 15 min. Then HRG (5 nm) plus Hst, or HRG plus control vehicle were added to fresh media. This treatment was repeated at 48 h, and growth was measured 24 h later by the MTS live cell assay as described in 'Materials and methods'. There were significant differences in the number of live MCF7 cells treated with either 100 or 300 nm Hst plus 5 nm HRG or treated with 5 nm HRG alone (Po0.001). Moreover, increasing Hst dosage correlated positively with % inhibition determined by linear regression (Po0.001). The 300 nm Hst plus HRG-treated BT474 cells were significantly different than those treated with HRG alone (P ¼ 0.01). Moreover, increasing Hst dosage from 0 to 300 nm significantly increased % inhibition as determined by linear regression (Po0.01). Similar results were observed in three experiments with each cell line Herstatin blocks heregulin growth and enhances tamoxifen sensitivity F Jhabvala-Romero et al when combined with tamoxifen, but only in HER-2 overexpressing breast cancers.
In conclusion, the activity of Hst in blocking HRGmediated proliferation, in enhancing sensitivity to growth inhibition by tamoxifen in HER-2 overexpressing cells, and the growth inhibitory action of purified Hst, suggest the feasibility and importance of further development as an anticancer agent.
Materials and methods
Cell culture and generation of stably transfected MCF7 clones MCF7 and BT474 human breast carcinoma cells were obtained from the American Type Culture Collection and maintained at 371C and 5% CO 2 in Dulbecco's modified Eagle's medium 13 (DMEM) containing 10% fetal bovine serum (FBS) and gentamicin (0.25 mg/ml) unless otherwise noted. Media and supplements were purchased from Gibco. Hst-expressing MCF7 clones were generated by transfection with human Hst in the mammalian vector pcDNA 3.1 or in pcDNA Hygro (Invitrogen) using Superfect reagent (Qiagen) as per the manufacturer's instructions. The HER-2 expression plasmid kindly provided by Dr Gaballe (Hutchinson Cancer Center) was used for the generation of HER-2 stably transfected MCF7 clones selected and cultured in media supplemented with 0.5 mg/ml G418 sulfate, or for HER-2 plus Hst clones selected with 0.2 mg/ml hygromycin and maintained in G418 plus hygromycin. Antibiotic resistant colonies were screened for the appropriate protein expression by Western blot analysis.
Antibodies and ligands
All antibodies were used at 1 : 1000 dilution unless indicated. Hst monoclonal antibody was a generous gift from Upstate Biotechnology. HER-3 and HER-4 polyclonal antibodies were purchased from Santa Cruz Biotechnology Inc. Polyclonal antibodies to p44/42 MAPK, Akt, phospho-p44/ 42 MAPK (Thr202/Tyr204), and phospho-Akt (Ser 273) were obtained from Cell Signaling Technology. Monoclonal anti-phosphotyrosine (anti-P-Tyr) antibody 4G10 was a generous gift from Dr Brian Druker (OHSU). Polyclonal anti-HER-2/neu antibody was characterized previously (Christianson et al., 1998) and diluted 1 : 10 000. Secondary antibodies conjugated to horseradish peroxidase including goat anti-mouse IgG (Pierce) and goat anti-rabbit IgG (BioRad) were used at 1 : 10 000 dilution. The monoclonal antibody herceptin manufactured by Genentech was purchased by prescription and used as an HER-2 inhibitor at a concentration of 1 mm. AG1478 was purchased from Sigma. Heregulin b1 (HRG) recombinant protein was purchased from Labvision Corporation. Human IGF-1 and FGF-2 were obtained from Austral Biologicals. 4-OH tamoxifen was purchased from Sigma.
Western blotting and immunoprecipitation
Cell monolayers were washed with phosphate-buffered saline (PBS) and lysed in mRIPA buffer (50 mm Tris-HCl (pH 7.0), 1.0% NP-40, 0.1% deoxycholic acid, 30 mm Na 3 VO 4 , 1 mm PMSF). Lysates were cleared by centrifugation and quantified using the Bradford Assay (Bio-Rad). Equal amounts (20 mg total protein per lane) were resolved by sodium dodecyl polyacrylamide gel electrophoresis (SDS-PAGE) in 10% polyacrylamide gels and transferred onto nitrocellulose membranes (Bio-Rad). Ponceau stain was used to assess protein transfer and also as a loading control. After blocking in 5% milk or in TBS-Tween plus 2.5% gelatin when using anti-P-Tyr, blots were incubated with primary antibody (at room temperature for 2 h or overnight at 41C) and secondary antibody (at room temperature for 30 min). For chemiluminescent detection, membranes were treated with SuperSignal West Dura (Pierce) and exposed to X-Ray film (X-Omat, Kodak). Blots were stripped by incubation with 1 Â stripping solution (Chemicon) at room temperature for 60 min. For immunoprecipitations, cell monolayers were lysed in MTG (50 mm Tris-HCl (pH 7.5), 10% glycerin, 1% NP-40, 10 mm Na 3 VO, 1 mm PMSF) and quantitated as described above. Protein (1 mg) was precipitated at 41C with 5 ml of primary antibody and 40 ml of Protein G-Sepharose (Amersham Pharmacia). Immunecomplexes were washed with MTG, resolved by SDS-PAGE, and analysed as a Western blot.
Detection of secreted Hst
Serum-free media conditioned by confluent MCF7, MCF7/ Hst1, or MCF7/Hst2 cells for 72 h were concentrated 50-fold using 15 Centriplus YM 30 centrifugal devices (Millipore) as per the manufacturer's instructions. Protein (20 mg) from concentrated media was analysed for Hst content as a Western blot.
Proliferation assays
Cells were plated (4 Â 10 4 ) in triplicate in 24-well plates, serum deprived by incubation in DMEM supplemented with 0.125%. FBS for 18 h, and treated with various concentrations of HRG in fresh media with 0.125% FBS. For tamoxifen treatment, cells were in 5% FBS. After 3 days, cell monolayers were washed with PBS and incubated for 2 h at 371C with 30 ml of MTS reagent [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl-2H-tetrazolium), inner salt] Aqueous One Solution (Promega) dissolved in 270 ml PBS per well. Absorbance readings were obtained at 492 nm in a Fluostar plate reader. To test the effect of purified Hst on cell growth, BT474 and MCF7 cells (4 Â 10 4 ) in triplicate in 24 wells were incubated in 0.5% FBS overnight, and treated in fresh media for 15 min with either purified Hst or control vehicle (20 mm Tris, 0.3 m NaCl, 0.15 m histidine, 10 mm PMSF, pH 8.0) before treatment with HRG (5 nm) plus Hst or HRG plus control vehicle. Control samples were treated with PBS. A similar treatment followed 2 days later, and proliferation was measured after 24 h by the MTS assay as described above.
Cocultures
MCF7 or BT474 cells were plated at an initial density of 1 Â 10 5 in six wells and then MCF7 or MCF7/Hst 1 cells (1 Â 10 5 ) were plated onto polycarbonate microporous inserts (4 mm pore size, Millipore). The cell layers were submerged in 1 ml of DMEM plus 10% FBS. At indicated times, the inserts were removed, and target cells were lysed for Western blot analysis.
Hst purification
Hst was cloned into the NcoI and XbaI sites, 5 0 and 3 0 , respectively, of pMT/BiP (Invitrogen). S2 insect cells were stably transfected with pMT/BiP-Hst and a plasmid for hygromycin selection (pCoHygro, Invitrogen) using Cellfectin reagent (Invitrogen) according to the manufacturer's instructions. S2 cells were then maintained in insect serum-free media with l-glutamine (JRH Biosciences) supplemented with 300 mg/ml hygromycin. Hst-expressing S2 cells (2 Â 10 6 ) were seeded in spinner flasks and grown to confluency (B15 Â 10 6 ), induced in fresh media with cupric sulfate (100 mm) overnight, and centrifuged for 20 min (4000 g). The serum-free media were subjected to Ni-NTA purification (Qiagen) according to the manufacturer's instructions. The wash buffer used was 20 mm Tris pH 8.5, 300 mm NaCl. The protein was eluted with wash buffer containing 0.15 m Histidine, 10 mm PMSF, and protease inhibitor tablets (Sigma). The Hst protein was assessed to be B90% pure indicated by SDS-PAGE resolution of 10 mg of Ni-NTA purified protein and Coomassie blue staining of the gels.
Abbreviations RTK, receptor tyrosine kinase; EGF, epidermal growth factor; HER, Human EGF receptors 1-4; EGFR, EGF receptor; HRG, heregulin; RT-PCR, reverse transcriptase-polymerase chain reaction; MAPK, mitogen-activated protein kinase; PI3K, phosphatidylinositol 3-kinase; SDS-PAGE, sodium dodecyl polyacrilamide-gel electrophoresis.
